Types of NK‑cell products further refine market taxonomy, influencing cost structure and regulatory pathways. Autologous NK cells are derived from the patient, offering personalized safety profiles but incurring higher manufacturing complexity, representing roughly 30 % of the product mix. Allogeneic NK cells sourced from healthy donors provide off‑the‑shelf scalability and currently capture about 35 % of the market, benefitting from standardized cryopreservation and rapid deployment. NK cell lines such as NK‑92 constitute approximately 15 % of offerings; their immortal nature simplifies expansion yet raises concerns about oncogenic potential, limiting use to controlled settings. Genetically engineered NK cells, including CAR‑NK constructs, are an emerging segment projected to exceed 10 % as clinical data mature, delivering enhanced specificity and persistence. Finally, cytokine‑activated NK cells (e.g., IL‑15‑primed) account for the remaining 10 %, primarily in early‑stage trials aiming to boost innate activity without permanent genetic alteration. Together, these categories shape the overall NK Cells market size by balancing manufacturing economics, regulatory risk, and therapeutic potency.
